Results 121 to 130 of about 1,457,629 (200)

The Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agents

open access: yesHaematologica, 2019
Chiara Tarantelli   +11 more
doaj   +1 more source

The Bruton tyrosine kinase inhibitor ibrutinib abrogates triggering receptor on myeloid cells 1-mediated neutrophil activation

open access: yesHaematologica, 2017
Nicole Stadler   +10 more
doaj   +1 more source

Healthy Participant Versus Patient Selection for Clinical Pharmacology Studies in Small‐Molecule Oncology Drug Development

open access: yes
Clinical and Translational Science, Volume 19, Issue 11, November 2026.
Paridhi Gupta   +3 more
wiley   +1 more source

Remibrutinib as a Therapeutic Option for Solar Urticaria

open access: yes
Photodermatology, Photoimmunology &Photomedicine, Volume 42, Issue 6, November 2026.
Joshua Mijares   +3 more
wiley   +1 more source

Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy

open access: yesHaematologica, 2019
Toby A. Eyre   +11 more
doaj   +1 more source

Invasive fungal infections after Bruton tyrosine kinase inhibitor treatment: a systematic review and meta-analysis. [PDF]

open access: yesBlood Adv
Srisurapanont K   +10 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy